Chengdu Kanghong Pharmaceutical

002773 · SZSE

Public Market Listing

002773SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Chengdu Kanghong Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Dopamine D3/D2 receptor (partial agonist)Small molecule
Schizophrenia
Phase 3
GABA-A receptorSmall molecule
Major Depressive Disorder

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
KH607Phase 3Major Depressive Disorder (MDD)
Est. primary completion 2027-12 · NCT07741240 · CT.gov ↗
What to watch
KH607Phase 3Major Depressive Disorder (MDD)
Est. primary completion 2027-12 · NCT07741331 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 May 2026Topline resultKH607Kanghong and Vanotech: Phase 2b study of KH607 in major depressive disorder met its primary endpoint
Kanghong Pharmaceutical and Vanotech · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$620M———report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2022-FY$505M$56M——report ↗